Mylan (MYL) Sued by Shareholder Over EpiPen Payments
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Mylan (NASDAQ: MYL) shares are on watch after an investor sued the company over allegations that it made misstatements on payments made to government health-insurance programs with respect to its EpiPen product, according to Bloomberg.
The lawsuit was filed in Manhattan court Tuesday.
Shares of Mylan are down around 1 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. health agency tells Grassley there is no EpiPen deal yet
- Costco to pay $11.75 million over lax U.S. pharmacy controls
- Outgoing FCC chair warns against overturning net neutrality
Create E-mail Alert Related CategoriesInsiders' Blog, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!